Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
Equities research analysts at Wedbush boosted their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R.
jhmi.edu Objective Although pancreatic ductal adenocarcinoma is considered a rapidly progressive disease, mathematical models estimate that it takes many years for an initiating pancreatic cancer cell ...
1Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: John Paul Shen, Department of Colon and Rectal Surgery, The ...
1Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P. R. China. 2Jiangsu Key Laboratory ...
In addition, HGSOC has no early detection biomarkers and is difficult to treat. "Epithelial high-grade serous ovarian carcinoma is the most common and deadliest subtype of ovarian cancer, accounting ...
upper tract urothelial carcinoma (UTUC), Muscle-invasive Urothelial Bladder Cancer, advanced differentiated thyroid cancer, papillary thyroid cancer, rectal cancer, platinum resistant high grade ...